Compare BIO-TECHNE Corp (TECH) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.52 (market cap $560.32M). The key difference: BIO-TECHNE Corp is far larger — about 20.3× Direxion Daily FTSE China Bull 3x Shares's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| TECH | YINN | |
|---|---|---|
Market Cap | $11.36B | $560.32M |
Volume | 5,390,331 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.61 | $52.69 |
52-Week Low | $43.31 | $21.45 |
Typical Hold Time | 63 Days | 25 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
YINN is trading at $23.56, down 2.97% with bearish technical indicators showing 18 sell signals versus 1 buy. The stock faces resistance at $24 with support at $23. Recent corporate actions include a $0.56 dividend scheduled for September 2026. Technical analysis indicates strong bearish momentum with moving averages unanimously negative.
The outlook remains challenging with bearish technical positioning and limited fundamental data availability. Key risks include market volatility and sector-specific headwinds. Investment opportunities may emerge if the stock stabilizes above support levels, but current momentum suggests continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
